BDSX — Biodesix, Inc.

Summary of Biodesix, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Q4 revenue reached $28.8 million, with total fiscal 2025 revenue at $88.5 million, marking an increase of 4,124% year-over-year.
• Lung Diagnostics Revenue: Q4 lung diagnostics revenue was $25.1 million, up 4,622% from the previous year. Excluding older claims, core organic growth was 40%.
• Test Volumes: 18,000 tests conducted in Q4, representing a 23% increase, with significant growth from primary care (up 67%).
• Gross Margins: Improved to 83% in Q4, up 400 basis points, and 81% for the fiscal year.
• Adjusted EBITDA: Positive adjusted EBITDA of $530,000 in Q4, the first positive quarter, with a fiscal year loss of $17.5 million (improved by 21%).
• Cash Position: Ended Q4 with $19.0 million in unrestricted cash and raised an additional $14.7 million post-quarter, providing a pro forma cash position of $33.7 million.

2. Strategic Updates and Business Highlights

• Commercial Strategy: Focus on lung nodule management through a three-tiered strategy targeting interventional pulmonologists, general pulmonologists, and primary care providers.
• Partnerships: Announced collaborations with Thermo Fisher Scientific and Bio-Rad Laboratories to develop and validate tests.
• Pipeline Development: Advancements in tests for lung cancer, including MRD tests and expansions of the VeriStrat test for immunotherapy selection in various cancers.
• Sales Force Expansion: Increased sales representatives from 65 to 97 in Q4, with plans to add six more per quarter in 2026.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Projected annual revenue between $106 million and $112 million, indicating a 23% growth over 2025.
• Continued Improvement: Expect sustained adjusted EBITDA positivity and operational leverage as the sales force gains experience and average revenue per test increases.

4. Bad News, Challenges, or Points of Concern

• Seasonality and Weather Impact: Anticipated revenue and volume decline in Q1 due to historical seasonality and recent weather disruptions.
• Sales Rep Productivity: Although new reps are expected to contribute to growth, the majority of Q4 growth came from existing reps, indicating a reliance on established personnel for immediate performance.
• Pipeline Launch Timing: Caution expressed regarding the commercialization of new tests without assured reimbursement, delaying potential launches.

5. Notable Q&A Insights

• Revenue Dynamics: Q1 is expected to see a step down in revenue and pricing due to seasonal effects and prior collections.
• Pipeline Development: Clarified that no new tests will be launched in the next 12 months, focusing instead on ensuring reimbursement for existing tests.
• Sales Force Allocation: Future hiring will be based on performance needs, with a focus on both primary care and pulmonology channels.
• HEDIS Guidelines: No new updates on HEDIS guidelines, but the company remains optimistic about future impacts on early cancer detection.

Overall, Biodesix, Inc. demonstrated significant growth in Q4 2025, achieving key financial milestones and expanding its commercial strategy while remaining cautious about upcoming challenges and market dynamics.